Q1 2026 earnings call recap: revenue beat, $90M-$92M guidance reaffirmed, sales rebuild, China headwind, cost cuts, CONVERT II ...

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended ...

Pulmonx Corp (LUNG) demonstrates resilience with operational momentum and strategic expansion despite revenue challenges.

Pulmonx (NASDAQ:LUNG) reported first-quarter 2026 worldwide revenue of $20.6 million, as management emphasized early progress ...

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today ...

Shares of Pulmonx (NASDAQ: LUNG) were crashing 53.7% lower as of 11:36 a.m. ET on Friday. The company announced its third-quarter results after the market closed on Thursday. However, Pulmonx's Q3 ...

Add Yahoo as a preferred source to see more of our stories on Google. By Sharnya G and Anuron Kumar Mitra (Reuters) - The U.S. Food and Drug Administration on Friday approved Pulmonx Inc's valve to ...

Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life Over 600,000 Japanese patients suffer from ...

Pulmonx Corp. Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates ...